Other
Gastrointestinal
2
Pipeline Programs↗
28
Active Trials↗
26
Companies Involved↗
Gastrointestinal is an early-stage landscape with 2 programs across 26 companies. The most active players are AstraZeneca, GSK, Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
157
clinical trials
Completed81 · 52%
Unknown status21 · 13%
Terminated20 · 13%
Recruiting15 · 10%
Not yet recruiting8 · 5%
Withdrawn6 · 4%
Other6 · 4%
Clinical Trials
Trial Activity
157 trials
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Recruiting·—·Phase 4·NCT07124351·15 enrolled
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Recruiting·—·Phase 1·NCT07001592·18 enrolled
Gastrointestinal Dysmotility on Aspiration Risk
Recruiting·—·Phase 4·NCT05455359·120 enrolled
The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)
Recruiting·—·Phase 4·NCT07303738·60 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)